FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361958246> ?p ?o ?g. }

• W4361958246 abstract "<div>AbstractPurpose:<p>Approved therapies for <i>EGFR</i> exon 20, <i>ERBB2</i> mutations, and <i>NRG1</i> fusions are currently lacking for non–small cell lung cancer and other cancers. Tarloxotinib is a prodrug that harnesses tumor hypoxia to generate high levels of a potent, covalent pan-HER tyrosine kinase inhibitor, tarloxotinib-effector (tarloxotinib-E), within the tumor microenvironment. This tumor-selective delivery mechanism was designed to minimize the dose-limiting toxicities that are characteristic of systemic inhibition of wild-type EGFR.</p>Experimental Design:<p>Novel and existing patient-derived cell lines and xenografts harboring <i>EGFR</i> exon 20 insertion mutations, <i>ERBB2</i> mutations and amplification, and <i>NRG1</i> fusions were tested <i>in vitro</i> and <i>in vivo</i> with tarloxotinib to determine its impact on cancer cell proliferation, apoptosis, and cell signaling.</p>Results:<p>Tarloxotinib-E inhibited cell signaling and proliferation in patient-derived cancer models <i>in vitro</i> by directly inhibiting phosphorylation and activation of EGFR, HER2, and HER2/HER3 heterodimers. <i>In vivo</i>, tarloxotinib induced tumor regression or growth inhibition in multiple murine xenograft models. Pharmacokinetic analysis confirmed markedly higher levels of tarloxotinib-E in tumor tissue than plasma or skin. Finally, a patient with lung adenocarcinoma harboring an <i>ERBB2</i> exon 20 p.A775_G776insYVMA mutation demonstrated a dramatic clinical response to tarloxotinib.</p>Conclusions:<p>Experimental data with tarloxotinib validate the novel mechanism of action of a hypoxia-activated prodrug in cancer models by concentrating active drug in the tumor versus normal tissue, and this activity can translate into clinical activity in patients.</p></div>" @default.
• W4361958246 created "2023-04-05" @default.
• W4361958246 creator A5003892152 @default.
• W4361958246 creator A5004389580 @default.
• W4361958246 creator A5014498790 @default.
• W4361958246 creator A5022348436 @default.
• W4361958246 creator A5024840477 @default.
• W4361958246 creator A5030727604 @default.
• W4361958246 creator A5034705456 @default.
• W4361958246 creator A5037183800 @default.
• W4361958246 creator A5043871151 @default.
• W4361958246 creator A5051692752 @default.
• W4361958246 creator A5082738447 @default.
• W4361958246 date "2023-03-31" @default.
• W4361958246 modified "2023-09-26" @default.
• W4361958246 title "Data from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes" @default.
• W4361958246 doi "https://doi.org/10.1158/1078-0432.c.6529985.v1" @default.
• W4361958246 hasPublicationYear "2023" @default.
• W4361958246 type Work @default.
• W4361958246 citedByCount "0" @default.
• W4361958246 crossrefType "posted-content" @default.
• W4361958246 hasAuthorship W4361958246A5003892152 @default.
• W4361958246 hasAuthorship W4361958246A5004389580 @default.
• W4361958246 hasAuthorship W4361958246A5014498790 @default.
• W4361958246 hasAuthorship W4361958246A5022348436 @default.
• W4361958246 hasAuthorship W4361958246A5024840477 @default.
• W4361958246 hasAuthorship W4361958246A5030727604 @default.
• W4361958246 hasAuthorship W4361958246A5034705456 @default.
• W4361958246 hasAuthorship W4361958246A5037183800 @default.
• W4361958246 hasAuthorship W4361958246A5043871151 @default.
• W4361958246 hasAuthorship W4361958246A5051692752 @default.
• W4361958246 hasAuthorship W4361958246A5082738447 @default.
• W4361958246 hasBestOaLocation W43619582462 @default.
• W4361958246 hasConcept C150903083 @default.
• W4361958246 hasConcept C153911025 @default.
• W4361958246 hasConcept C185592680 @default.
• W4361958246 hasConcept C190283241 @default.
• W4361958246 hasConcept C207001950 @default.
• W4361958246 hasConcept C502942594 @default.
• W4361958246 hasConcept C55493867 @default.
• W4361958246 hasConcept C62112901 @default.
• W4361958246 hasConcept C86803240 @default.
• W4361958246 hasConceptScore W4361958246C150903083 @default.
• W4361958246 hasConceptScore W4361958246C153911025 @default.
• W4361958246 hasConceptScore W4361958246C185592680 @default.
• W4361958246 hasConceptScore W4361958246C190283241 @default.
• W4361958246 hasConceptScore W4361958246C207001950 @default.
• W4361958246 hasConceptScore W4361958246C502942594 @default.
• W4361958246 hasConceptScore W4361958246C55493867 @default.
• W4361958246 hasConceptScore W4361958246C62112901 @default.
• W4361958246 hasConceptScore W4361958246C86803240 @default.
• W4361958246 hasLocation W43619582461 @default.
• W4361958246 hasLocation W43619582462 @default.
• W4361958246 hasOpenAccess W4361958246 @default.
• W4361958246 hasPrimaryLocation W43619582461 @default.
• W4361958246 hasRelatedWork W2040088376 @default.
• W4361958246 hasRelatedWork W2050306700 @default.
• W4361958246 hasRelatedWork W2349672624 @default.
• W4361958246 hasRelatedWork W2367700600 @default.
• W4361958246 hasRelatedWork W2369212495 @default.
• W4361958246 hasRelatedWork W2369900537 @default.
• W4361958246 hasRelatedWork W2382765128 @default.
• W4361958246 hasRelatedWork W2389995618 @default.
• W4361958246 hasRelatedWork W2393123779 @default.
• W4361958246 hasRelatedWork W2414946262 @default.
• W4361958246 isParatext "false" @default.
• W4361958246 isRetracted "false" @default.
• W4361958246 workType "article" @default.